GeoVax Labs Inc/$GOVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GeoVax Labs Inc
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Ticker
$GOVX
Sector
Primary listing
Employees
19
Headquarters
Website
GeoVax Labs Inc Metrics
BasicAdvanced
$3.3m
-
-$22.40
3.80
-
Price and volume
Market cap
$3.3m
Beta
3.8
52-week high
$4.40
52-week low
$0.96
Average daily volume
232k
Financial strength
Current ratio
2.744
Quick ratio
1.593
Long term debt to equity
15.164
Total debt to equity
22.043
Profitability
EBITDA (TTM)
-21.57
Gross margin (TTM)
-628.02%
Net profit margin (TTM)
-862.34%
Operating margin (TTM)
-869.35%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-186.57%
Return on equity (TTM)
-483.79%
Valuation
Price to revenue (TTM)
0.445
Price to book
0.52
Price to tangible book (TTM)
0.52
Price to free cash flow (TTM)
-0.051
Free cash flow yield (TTM)
-1,942.50%
Free cash flow per share (TTM)
-22.434
Growth
Revenue change (TTM)
-37.06%
Earnings per share change (TTM)
-81.41%
3-year revenue growth (CAGR)
212.55%
10-year revenue growth (CAGR)
19.25%
3-year earnings per share growth (CAGR)
-58.34%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GeoVax Labs Inc stock?
GeoVax Labs Inc (GOVX) has a market cap of $3.3M as of May 04, 2026.
What is the P/E ratio for GeoVax Labs Inc stock?
The price to earnings (P/E) ratio for GeoVax Labs Inc (GOVX) stock is 0 as of May 04, 2026.
Does GeoVax Labs Inc stock pay dividends?
No, GeoVax Labs Inc (GOVX) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next GeoVax Labs Inc dividend payment date?
GeoVax Labs Inc (GOVX) stock does not pay dividends to its shareholders.
What is the beta indicator for GeoVax Labs Inc?
GeoVax Labs Inc (GOVX) has a beta rating of 3.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.